Readiness is not a decorative score
A useful readiness view separates progress from confidence, evidence quality, unanswered questions, and launch-gating exposure.
Launch Intelligence
Pharmaceutical launch research should improve a decision—not decorate a website.
UEM follows the scientific, market, access, field, and operating questions that shape commercialization decisions across major therapeutic areas.
Sources · Context · Synthesis · Decisions
Research library
Thirteen therapeutic areas connected by launch decisions.
The therapeutic context changes, but the leadership questions remain connected: evidence, differentiation, access, organization, field execution, patient friction, governance, and the timing of consequential choices.
01Cardiology
02CNS & neurology
03Dermatology
04Endocrinology & metabolic health
05Gastroenterology
06Immunology & inflammation
07Infectious disease
08Musculoskeletal & bone health
09Nephrology & urology
10Oncology
11Ophthalmology
12Rare disease
13Respiratory disease
The proof standard
Research earns value when it changes a decision.
UEM evaluates intelligence by its source quality, currency, relevance, and ability to clarify what leadership should decide or investigate next.
AI does not rewrite launch reality
AI may summarize, structure, compare, and surface gaps. It should not silently change readiness state, close decisions, manufacture evidence, or present unsupported certainty.
A conclusion should show its basis
Material recommendations should make their sources, assumptions, limitations, and decision consequences visible to the people accountable for acting.
Need current intelligence?
Ask for the decision context, not a generic download.
Tell us the asset, launch stage, therapeutic area, and commercial decision. We will be explicit about what UEM can support now and what requires additional research or expert review.